Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EU research fights killer viruses’ stubborn resistance to drugs

29.06.2004


Viruses’ growing resistance to drugs means diseases such as hepatitis B and C are increasingly difficult to treat. New pandemics may arise with unforeseeable consequences. The EU is therefore contributing € 9 million to the “Vigilance against Viral Resistance” (VIRGIL) project, to be launched today in Lyon (France). It will start by addressing drug resistance in viral hepatitis and influenza, but will broaden its scope to other viruses. The network will be based on research and technological platforms to monitor existing, and anticipate future, drug resistance. One platform will monitor, test and improve the management of antiviral drug resistance in patients while another will show how resistance occurs and help understand patient-related (immune/genetic) factors causing viral resistance. Other platforms for drugs and pharmacology and for innovation and technology will allow anticipation of ways to rapidly overcome drug resistance. Finally, a societal impact platform will assess the network’s benefit for medicine and patients’ quality of life. VIRGIL, coordinated by Lyon’s INSERM research centre, will gather 55 key European field experts from 12 countries, including 7 partners from industry.

“The heavy use of antibiotics, particularly in hospitals, hastens mutations in bacteria which bring about drug resistance. The same happens in viruses when antiviral drugs are used extensively,” European Research Commissioner Philippe Busquin said. “VIRGIL complements a €30 million EU research investment into antimicrobial drug resistance over the past two years to address this growing problem. Through collaboration between European academic researchers, the pharmaceutical industry, clinicians and public health authorities the network will help overcome problems associated with viral drug resistance to help save lives.”

Killer diseases: on the rampage?



Viral hepatitis causes chronic liver disease, including cirrhosis and liver cancer. Although a safe and efficient vaccine does exist for hepatitis B, over 350 million people around the world are now chronically infected with this virus. For hepatitis C, no vaccine exists and over 1% of Europeans are carriers. Intensive clinical use of the few available drugs has led to rapidly emerging drug resistance for some viruses so that these drugs are no longer efficient.

Yearly epidemics of new flu strains infect 5-15% of the world population with up to 500.000 deaths. Genetic changes in the influenza virus may lead to severe epidemics of global dimension (pandemics), such as the Spanish flu of 1918 that killed over 40 million people. Experts now fear another pandemic may arise shortly with unforeseeable consequences. Access to efficient drugs will be essential in such a catastrophic scenario. Again, the virus is likely to develop drug resistance.

EU research saves lives and money

The VIRGIL network will be able to rapidly and reliably determine resistance to new drugs and the drug susceptibility of emerging viral strains based on new treatments. The network aims to link up with the antiviral drug producing pharmaceutical industry in a cost-effective partnership that will help to ensure longer access to treatment and cure for the patients. This will help contain the socio-economic burden of viral resistance, now representing a major health problem with higher health care and drug development costs.

Fabio Fabbi | EU Commission
Further information:
http://www.europa.eu.int
http://www.virgil-net.org

More articles from Agricultural and Forestry Science:

nachricht Plasma-zapping process could yield trans fat-free soybean oil product
02.12.2016 | Purdue University

nachricht New findings about the deformed wing virus, a major factor in honey bee colony mortality
11.11.2016 | Veterinärmedizinische Universität Wien

All articles from Agricultural and Forestry Science >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>